Deconvoluting low yield from weak potency in direct-to-biology workflows with machine learning
Description
High throughput and rapid biological evaluation of small molecules is an essential factor in drug discovery and development. Direct-to-biology (D2B), whereby compound purification is foregone, has emerged as a viable technique in time efficient
